That is one possibility. Another is that by making motor activity a secondary endpoint, they are collecting data which provides a glimpse into whether 2-73 is worth another trial with motor tremors as a primary endpoint. The cost of gathering that data is minimal. If it does show promise that would be another indication that 2-73 could treat.
Or more likely both possibilities are being explored, both the up side and the down side.
I think the main reason is Anavex hopes to see efficacy in the motor symptoms of PD as it is a larger indication. Although the muscarinic activity of A273 might worsen the tremor, the S1R activity may improve it. Its unclear which effect should be greater. Will we see 5 - 3 = 2 or 3 - 5 = -2?
Market Data 
Markets 
AI
